Barings BDC, Inc. BBDC is slated to announce third-quarter 2020 results on Nov 11, after market close. Its earnings for the to-be-reported quarter are expected to have declined year over year.In the last reported quarter, the company’s earnings lagged the Zacks Consensus Estimate. Results were affected a fall in investment income, partly offset by lower expenses.Barings BDC has an unimpressive earnings surprise history. Its earnings lagged the Zacks Consensus Estimate in three of the trailing four quarters, the negative surprise being 4.79%, on average. BARINGS BDC, INC. Price and EPS Surprise BARINGS BDC, INC. price-eps-surprise | BARINGS BDC, INC. Quote Before we take a look at what our quantitative model predicts for the third quarter, let’s check the factors that are likely to have influenced its performance.Factors at PlayGiven the low interest rates environment during the third quarter, interest income from investment, and other income are likely to have been negatively impacted. Also, slowdown in the middle market lending due to the pandemic is expected to have kept net investment income under pressure during the third quarter.On the cost front, Barings BDC has been witnessing lower expenses over the past several quarters. Moreover, as the company continues to make efforts at costs savings, operating expenses are likely to have been low in the to-be-reported quarter.What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Barings BDC this season. This is because it doesn’t have the right combination of the two key ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Earnings ESP: Barings BDC has an Earnings ESP of -1.64%.Zacks Rank: The company currently carries a Zacks Rank #3.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Notably, activities of the company in the third quarter were inadequate to win analysts’ confidence. As a result, the Zacks Consensus Estimate for earnings of 15 cents remained unchanged over the past seven days. It indicates a fall of 6.3% from the year-ago reported number.However, the Zacks Consensus Estimate for sales is pegged at $16.9 million, which reflects 12.6% growth.Earnings Dates of Other Finance StocksAmong other finance stocks, Golub Capital BDC, Inc. GBDC and Gladstone Capital Corporation GLAD are scheduled to release results on Nov 23 and Nov 11, respectively. Oaktree Strategic Income Corp. OCSI will report on Nov 19.Breakout Biotech Stocks with Triple-Digit Profit PotentialThe biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Golub Capital BDC, Inc. (GBDC): Free Stock Analysis Report Gladstone Capital Corporation (GLAD): Free Stock Analysis Report Oaktree Strategic Income Corp. (OCSI): Free Stock Analysis Report BARINGS BDC, INC. (BBDC): Free Stock Analysis Report To read this article on Zacks.com click here.